2026 Myeloma Treatment Guidelines of the Turkish Myeloma Study Group
Clinical Lymphoma, Myeloma and Leukemia, 2026 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Derleme
- Basım Tarihi: 2026
- Doi Numarası: 10.1016/j.clml.2026.08.008
- Dergi Adı: Clinical Lymphoma, Myeloma and Leukemia
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, CINAHL, EMBASE, MEDLINE, Biomedical Reference Collection: Corporate Edition (EBSCO)
- Anahtar Kelimeler: Measurable residual disease, Multiple myeloma, Risk stratification, Therapeutic sequencing, Türkiye
- İstanbul Üniversitesi Adresli: Evet
Özet
The treatment landscape of multiple myeloma (MM) is evolving rapidly, driven by the approval of new therapies and the increasing integration of advanced response-assessment tools, including measurable residual disease (MRD). These developments have made treatment algorithms increasingly complex. Furthermore, access to novel therapies is often delayed and varies from 1 country to another, necessitating national-level treatment guidelines. Under the auspices of the Turkish Society of Hematology, we have been publishing national treatment guidelines. The first national myeloma guideline was published in 2020 and subsequently updated in 2024. Building on recently published registrational data and the 2025 EHA–EMN guidelines, we present the second update of the Turkish Myeloma Treatment Guidelines. We aim to include all currently approved therapies as well as emerging therapies likely to be approved in the near future. This approach guides Turkish hematologists in daily routine practice when needed. This guidance aligns with internationally accepted standards and explicitly considers reimbursement protocols and their impact on local implementation. This effort aims to support new drug approvals and facilitate the implementation of diagnostic and response-assessment tools in routine clinical practice in Türkiye. Our objective is to promote consistent, equitable, and adaptable myeloma care across Türkiye.